February 9, 2023

In the context of our collaboration with various stakeholders in the T2EVOLVE project, we are happy to share that the T2EVOLVE-QUALITOP European patient survey on CAR T-cell therapy is now open !

This survey will help to understand patients’ experiences with CAR T-cell therapy, evaluate the impact of this treatment on quality of life and identify unmet needs. With this information we aim to improve quality of life in patients receiving CAR T-cell therapy and their carers by optimizing support and improving the CAR T-cell treatment journey.

All European adult patients (≥ 18 years) who received CAR T-cell therapy for a hematologic malignancy (no specific indication required) can participate by filling in a digital survey.

Now, we need you!

If you are a patient treated with CAR T-cell therapy for a hematologic malignancy in Europe we would like to invite you to share your experiences with us by participating in our survey!

If you are not a patient but you are in close contact with patients who receive CAR T-cell therapy (e.g. a patient association, hematologist, nurse or other healthcare professional) we would like to invite you to help us by sharing this survey with patients! 🖨️

You can use the attached QR code or the following link to access the survey (password: T2EVOLVE_QUALITOP): https://t2evolve.fyi/patientsurvey

The survey is available in English, French, German, Spanish, Italian, Portuguese and Dutch.

The survey will be open until the 30th of April.